Literature DB >> 26404466

Science and Art of Cell-Based Ocular Surface Regeneration.

Vivek Singh1, Sachin Shukla1, Charanya Ramachandran1, Dilip Kumar Mishra2, Kishore R Katikireddy3, Ikeda Lal4, Sunil K Chauhan3, Virender S Sangwan5.   

Abstract

The potential cause of blindness worldwide includes diseases of the cornea, ocular surface (limbal stem cell deficiency, allergic conjunctivitis, dry eye diseases), and retinal diseases. The presence of stem cells (limbal stem cells) in the basal region of the limbus makes it an important tool for the ocular regeneration and also in maintaining the transparency of eye by replacing the corneal epithelium continuously. Various surgical modalities have been developed like cultured limbal epithelial transplantation, cultured oral mucosal epithelial transplantation, simple limbal epithelial transplantation, etc., utilizing the cell-based regenerative properties to treat limbal disorder. Cell-based therapies for ocular repair and regeneration comprise a major hope by therapies involving the mesenchymal stem cells, embryonic stem cells, and limbal stem cells for the restoration of vision in individuals whose ocular tissue has been irreversibly damaged by disease or trauma. This review explores critical needs in human disease mainly the ocular problem where cell-based therapeutics is exceptionally well suited and also the use of animal models, various artificial scaffolds, as well as advancement in clinical technique to challenge the current demand to overcome corneal blindness.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allograft; Animal model for ocular disorder; Autograft; Cell-based therapy; Corneal scaffold; Limbal stem cell deficiency; Limbal transplantation; Mesenchymal stem cells

Mesh:

Year:  2015        PMID: 26404466     DOI: 10.1016/bs.ircmb.2015.07.001

Source DB:  PubMed          Journal:  Int Rev Cell Mol Biol        ISSN: 1937-6448            Impact factor:   6.813


  7 in total

1.  Issues of rehabilitation of the patients with symblepharon using oral mucosal autografts.

Authors:  Marina B Gushchina; Alexander V Gushchin; Daria S Afanasyeva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-10-19       Impact factor: 3.117

Review 2.  Molecular mechanisms and treatments for ocular symblephara.

Authors:  Aditi Swarup; Christopher N Ta; Albert Y Wu
Journal:  Surv Ophthalmol       Date:  2021-04-29       Impact factor: 6.048

3.  Optimizing the role of limbal explant size and source in determining the outcomes of limbal transplantation: An in vitro study.

Authors:  Abhinav Reddy Kethiri; Sayan Basu; Sachin Shukla; Virender Singh Sangwan; Vivek Singh
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

4.  Characterization of limbal explant sites: Optimization of stem cell outgrowth in in vitro culture.

Authors:  Pattama Ekpo; Naharuthai Inthasin; Sutthicha Matamnan; Patimaporn Wongprompitak; Methichit Wattanapanitch; Chawikan Boonwong; Chareenun Chirapapaisan; Panotsom Ngowyutagon; Mongkol Uiprasertkul; Pinnita Prabhasawat; Wiwit Tantibhedhyangkul
Journal:  PLoS One       Date:  2020-05-14       Impact factor: 3.240

5.  Human Cadaveric Donor Cornea Derived Extra Cellular Matrix Microparticles for Minimally Invasive Healing/Regeneration of Corneal Wounds.

Authors:  Arun Chandru; Parinita Agrawal; Sanjay Kumar Ojha; Kamalnath Selvakumar; Vaishnavi K Shiva; Tanmay Gharat; Shivaram Selvam; Midhun Ben Thomas; Mukesh Damala; Deeksha Prasad; Sayan Basu; Tuhin Bhowmick; Virender Singh Sangwan; Vivek Singh
Journal:  Biomolecules       Date:  2021-04-02

6.  Novel detection of stem cell niche within the stroma of limbus in the rabbit during postnatal development.

Authors:  Nada Abdellah; Sara M M El- Desoky
Journal:  Sci Rep       Date:  2022-08-12       Impact factor: 4.996

7.  Dynamic Optical Coherence Elastography of the Anterior Eye: Understanding the Biomechanics of the Limbus.

Authors:  Fernando Zvietcovich; Achuth Nair; Manmohan Singh; Salavat R Aglyamov; Michael D Twa; Kirill V Larin
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-11-02       Impact factor: 4.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.